维得利珠单抗联合美沙拉嗪治疗炎症性肠病的临床疗效及安全性分析

doi:10.3969/j.issn.1671-7171.2024.01.026

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1182 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the clinical efficacy and safety of combination therapy with Vedolizumab and Mesalazine in the treatment of inflammatory bowel disease.【Methods】 A total of 84 patients with inflammatory bowel disease admitted to the First Affiliated Hospital of Nanyang Medical College from January 2021 to December 2022 were selected. They were randomly divided into a conventional group and a combination group using a random number table method, with 42 patients in each group. The conventional group was given Mesalazine, while the combination group was given Vedrizumab in addition to the conventional group. The treatment effect was observed in both groups at week 8. We compared the clinical efficacy, peripheral blood inflammatory factors [serum interleukin-4 (IL-4), interleukin-17 (IL-17)], and inflammatory bowel disease quality of life questionnaire (IBDQ) scores between two groups, and recorded the occurrence of adverse drug reactions during treatment.【Results】 The total effective rate of the combined group was 95.24%(40/42), which was higher than the conventional group's 78.57%(33/42), and the difference was statistically significant (χ²=5.126, P<0.05). After treatment, the serum levels of IL-4 and IL-17 in both groups of patients were lower than before treatment, and the combined group was lower than the conventional group, with statistical significance (P<0.05). The IBDQ scores of the conventional group and the combination group before treatment were (115.89±12.93) points and (113.27±11.85) points, respectively. After treatment, the scores of the two groups were (182.34±15.48) points and (198.15±7.26) points, respectively. After treatment, the IBDQ scores of the two groups of patients were higher than before treatment, and the combination group was higher than the conventional group, with a statistically significant difference (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ²=0.156, P=0.693). 【Conclusion】 The combination of Vedolizumab and Mesalazine in the treatment of inflammatory bowel disease can enhance the therapeutic effect, inhibit the synthesis of inflammatory factors, improve the quality of life of patients, and have good safety.

Key words： Inflammatory Bowel Diseases/DT Antibodies, Monoclonal/TU Mesalamine/TU Treatment Outcome

Received: 14 March 2023

PACS:

R574

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Zhenzhen
	ZHU Bingyang
	FANG Jintao

Cite this article:

MA Zhenzhen,ZHU Bingyang,FANG Jintao. Clinical Efficacy and Safety Analysis of the Combination of Vedolizumab and Mesalazine in the Treatment of Inflammatory Bowel Disease[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 95-98.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.01.026 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I1/95

[1] HAIFER C, PARAMSOTHY S, KAAKOUSH N O, et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial[J].Lancet Gastroenterol Hepatol,2022, 7(2):141-142.
[2] CABALLOL B, GUDINO V, PANES J, et al. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development[J].Expert Opin Investig Drugs,2021,30(9):931-946.
[3] GHOSH S, SANCHEZ G Y, ZHOU W, et al. Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis[J].J Crohns Colitis,2021,15(12):2022-2030.
[4] LUKIN D, FALECK D, XU R, et al. Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis[J].Clin Gastroenterol Hepatol,2022, 20(1):126-135.
[5] MAÑOSA M, FERNÁNDEZ-CLOTET A, NOS P, et al. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry[J].Dig Liver Dis,2023, 55(1):46-52.
[6] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2018年?北京)[J].中国实用内科杂志,2018,38(9):796-813.
[7] ZAVALA-SOLARES M R, SALAZAR-SALAS L, YAMAMOTO-FURUSHO J K. Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease[J].Gastroenterol Hepatol,2021,44(10):711-718.
[8] ONALI S, PUGLIESE D, CAPRIOLI F A, et al. An objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients' failure to TNF-alpha inhibitors[J].Am J Gastroenterol,2022, 117(8):1279-1287.
[9] 姚建国. 复方甘草酸苷联合美沙拉嗪治疗慢性溃疡性结肠炎的临床研究[J].中国药物与临床, 2021, 21(13):2316-2318.
[10] 潘春生, 王维, 王科菊. 维多珠单抗联合美沙拉嗪治疗溃疡性结肠炎患者的效果及对肠黏膜屏障功能和免疫功能的影响[J].中国医药, 2021, 16(12):1837-1840.
[11] 尹硕鑫, 张涛, 王舒萍,等. 维得利珠单抗诱导和维持炎症性肠病疗效Meta分析[J].陕西医学杂志, 2022, 51(1):103-110.
[12] 刘思雪, 钟娃. 维得利珠单抗治疗炎症性肠病的临床疗效分析[J].新医学, 2022, 53(10):767-773.
[13] 王冰心, 闫欢欢, 党小红. 维多珠单抗治疗活动性炎症性肠病疗效和安全性的评价[J].胃肠病学, 2019, 24(7):420-426.
[14] 芦波, 刘昭诗, 郑威扬, 等. 维得利珠单抗对炎症性肠病患者的短期疗效及安全性[J].中华医学杂志, 2022, 102(42):3388-3394.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 296-298.